Drug Type Antibody drug conjugate (ADC) |
Synonyms Patritumab-DX-8951 conjugate, HER3-DXD, MK-1022 + [3] |
Target |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationPriority Review (US), Breakthrough Therapy (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | NDA/BLA | US | 22 Dec 2023 | |
EGFR-mutated non-small Cell Lung Cancer | NDA/BLA | US | 22 Dec 2023 | |
Non-squamous non-small cell lung cancer | Phase 3 | US | 08 Jul 2022 | |
Non-squamous non-small cell lung cancer | Phase 3 | CN | 08 Jul 2022 | |
Non-squamous non-small cell lung cancer | Phase 3 | JP | 08 Jul 2022 | |
Non-squamous non-small cell lung cancer | Phase 3 | AU | 08 Jul 2022 | |
Non-squamous non-small cell lung cancer | Phase 3 | AT | 08 Jul 2022 | |
Non-squamous non-small cell lung cancer | Phase 3 | BE | 08 Jul 2022 | |
Non-squamous non-small cell lung cancer | Phase 3 | CA | 08 Jul 2022 | |
Non-squamous non-small cell lung cancer | Phase 3 | FR | 08 Jul 2022 |
Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 225 | rwppwmzkku(tgajjnltcg) = vtxuqrgvut xlgtyfemmg (ssseffutjj ) View more | Positive | 22 Mar 2024 | ||
Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR mutation | 95 | ctfuowcgxo(hbdzhzxeeo) = gxryrwtnzb oorhptblhu (akyxcixlcr ) View more | Positive | 22 Oct 2023 | ||
(Prior local CNS-directed radiotherapy <6 mo from start) | ctfuowcgxo(hbdzhzxeeo) = pzgukaygax oorhptblhu (akyxcixlcr ) View more | ||||||
Phase 1/2 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | - | (Prior EGFR TKI (any) and PBC) | zdedkikolh(edgvutzpiu) = znslnwkqdz eaximeifwp (hgcdriuufy ) View more | Positive | 10 Sep 2023 | |
(Prior 3G EGFR TKI and PBC) | zdedkikolh(edgvutzpiu) = qzzkeruxuy eaximeifwp (hgcdriuufy ) View more | ||||||
NCT04699630 (ASCO2023) Manual | Phase 2 | 60 | rapzzzcqtq(xewxgticcc) = wvbszmdhxn zvvefqytho (ckykyeafsz, 23.1 - 48.1) View more | Positive | 31 May 2023 | ||
Not Applicable | - | nscnihkrum(xzwukwebyb) = reprogrammed cell cycle progression from G2/M arrest to G1 arrest kvbhxarbkd (zatjbuxtaf ) | - | 15 Jun 2022 | |||
NCT03260491 (ASCO2022) Manual | Phase 1 | 47 | jnxxnlfxme(tcdiivyspj) = pirhasmomi lnygvaxlby (mfpulyllav, 16 - 43) View more | Positive | 02 Jun 2022 | ||
Phase 1/2 | 182 | bdhxpfhfmx(nzhttpeuza) = kpnvmwwziw omaymvxoja (oahofdyxby ) View more | - | 02 Jun 2022 | |||
Early Phase 1 | 78 | vsvneybgew(yfczzhfudt) = Overall, 74 (95%) patients reported any grade AEs olhnwmfeud (zgxacncahn ) View more | - | 03 May 2022 | |||
Early Phase 1 | Breast Cancer ERBB3 Expression | 30 | xidkjbglkd(cgyxdteyfo) = a statistically significant increase in CelTIL was observed between paired samples (p=0.028) ddriyfvmnp (zfkweqdnqd ) View more | Positive | 15 Feb 2022 | ||
Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 57 | krqrdjgmec(lcwelwnsrc) = rayxmsnozq abdzuejznp (ekkwfnenda, 26.0 - 52.4) View more | Positive | 21 Sep 2021 |